Emcure Pharmaceuticals
 | |
| Type | MNC (JVs and subsidiaries) |
|---|---|
| Industry | Pharmaceutical |
| Founded | 1983 |
| Founder | Satish Mehta (CEO & MD) |
| Headquarters | Hinjewadi, Pune, India |
Area served | Worldwide |
Key people | Namita Thapar (Executive Director) Vikas Thapar (President - Corporate Dev & Strategy) Samit Mehta (President - R&D) |
| Website | www.emcure.com |
Emcure Pharmaceuticals Limited is an Indian multinational pharmaceutical company headquartered in Pune, Maharashtra. Emcure's product portfolio includes tablets, capsules (both Softgel capsules and hard-gel capsules) and injectables.[1][2]
Indian plants[edit]
This is the list of Manufacturing facilities based in India[3] -
- Solid Dosage facility at Hinjwadi - In 2006, Emcure received US FDA approval for its solid dosages facility at Hinjwadi, Pune. The plant manufactures solid oral formulations for the international regulated markets, but is under FDA warning letter
- Small volume parenteral facility at Hinjawadi - US FDA, UK MHRA approved. Has lyophilization and pfs capability, but is under FDA warning letter
- Oncology injectable facility at Hinjawadi, but is under FDA warning letter
- Solid Orals facilities at Jammu and Bhosari
- API facility at Kurkumbh- US FDA approved
- Biotech facility at Hinjawadi
- R&D center at Gandhinagar and plant at Sanand, Ahmedabad.- Sanand facility is US FDA approved
US plant[edit]
USA - The company has a manufacturing facility and R&D center in East Brunswick, New Jersey, USA.[3]
Capital markets[edit]
Emcure is planning to raise money through an initial public offering for some time now[4] In 2014, Blackstone sold its stake in Emcure to Bain Capital[5]
Recalls[edit]
In 2010, Pfizer had to recall three batches of an anti-bacterial product from the US market due to presence of Bacillus anthracis, Penicillium chrysogenum & E. coli in some samples.[6] Teva recalled several batches of two products due to white tablets showing presence of Yersinia pestis in 2011.[7]
AIDS Initiative[edit]
Emcure voices its concerns on HIV/AIDS through its "Let's fight AIDS together" initiative and supplies Antiretroviral drugs to Africa, Asia Pacific and CIS. As a part of its corporate social responsibility it supports 'Taal', a pharmacy for HIV/AIDS patients run by HIV/AIDS patients.
Emcure has license agreements with Bristol-Myers Squibb for Atazanavir[8] and Gilead Sciences for Tenofovir as part of their Global Access Programs.
Anticancer portfolio[edit]
Roche has signed a deal with Emcure for manufacturing its blockbuster anticancer drugs Herceptin and Mabthera in India.[6] Under this programme the cancer drugs shall be made available to the developing world at an affordable 'cut-price' version.[9]
Price fixing[edit]
Heritage Pharmaceuticals, a division of Emcure has entered into a deferred prosecution agreement[10] with the United States Department of Justice, Antitrust Division ("DOJ") relating to a one-count Information for a conspiracy involving glyburide. In conjunction with the DPA, Heritage will pay a $225,000 fine.
In addition, the Company separately agreed to a settlement with the United States Department of Justice, Civil Division to resolve potential civil liability under the False Claims Act in connection with the antitrust conduct. Under the terms of the settlement, the Company has agreed to pay $7.1 million. Heritage has agreed to pay $7.1 million as part of a settlement with DOJ's Civil Division to resolve allegations of selling drugs at the artificially inflated prices, which resulted in claims submitted to or purchases by federal healthcare programs. After the scandal, Emcure renamed Heritage to Avet Pharma [11] - opposite of Teva, since many new executives joined after stepping down from Teva.
Controversies[edit]
There are allegations that Emcure (through its sister company Gennova) stole the technology of vaccine production by breaching contract with HDT Bio.[12] Earlier Emcure broke ties with Roche in similar way.[13] In the Drug Price Fixing case, Emcure CEO Satish Mehta was alleged to collude and conspire with Rajiv Malik to jack up prices of essential drugs.[14]
The USFDA had given Warning Letter for data integrity manipulation problems at Emcure plants which shows a trend of this company and management.[15]
References[edit]
- ^ "Emcure Pharmaceuticals | Leading Global Pharmaceutical Company". Emcure. Retrieved 2021-08-23.
- ^ "Emcure Pharmaceuticals: Latest News & Videos, Photos about Emcure Pharmaceuticals | The Economic Times - Page 1". The Economic Times. Retrieved 2021-08-23.
- ^ a b "Manufacturing | Emcure Pharmaceuticals". Emcure. Retrieved 2021-08-23.
- ^ "Latest News: India News | Latest Business News | BSE | IPO News". Moneycontrol.
- ^ "Blackstone to sell Emcure Pharmaceuticals stake to Bain Capital - Indian Express". archive.indianexpress.com.
- ^ a b "Business News Today: Read Latest Business news, India Business News Live, Share Market & Economy News". The Economic Times.
- ^ "Archived copy". Archived from the original on 2011-05-20. Retrieved 2012-04-25.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ Bureau, Our Corporate (February 17, 2006). "Bristol-Myers outsources AIDS drug to Emcure" – via Business Standard.
- ^ "Archived copy". Archived from the original on 2012-08-01. Retrieved 2012-04-12.
{{cite web}}: CS1 maint: archived copy as title (link) - ^ "Pharmaceutical Company Admits to Price Fixing in Violation of Antitrust Law, Resolves Related False Claims Act Violations". www.justice.gov. May 31, 2019.
- ^ Avet formerly Heritage
- ^ https://www.reuters.com/legal/government/lawsuit-says-indias-emcure-stole-covid-19-vaccine-secrets-ipo-2022-03-22/[bare URL]
- ^ https://m.economictimes.com/industry/healthcare/biotech/pharmaceuticals/roche-emcure-may-end-pact-to-make-2-blockbuster-drugs/articleshow/59745422.cms
- ^ DoJ goes after Indian Billionaire
- ^ Warning letter by USFDA - Data Integrity manipulation problem
External links[edit]
| Founders |  | ||||
|---|---|---|---|---|---|
| Notable executives |
| ||||
| Subsidiaries |
| ||||
| Investment Holdings | |||||
